569 related articles for article (PubMed ID: 26414502)
21. The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors.
Piccinelli S; Romee R; Shapiro RM
Semin Hematol; 2023 Jan; 60(1):42-51. PubMed ID: 37080710
[TBL] [Abstract][Full Text] [Related]
22. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
Guo H; Qian X
Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
[TBL] [Abstract][Full Text] [Related]
23. Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer.
Sabry M; Lowdell MW
Stem Cells Transl Med; 2020 Sep; 9(9):974-984. PubMed ID: 32416056
[TBL] [Abstract][Full Text] [Related]
24. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic applications: natural killer cells in the clinic.
Miller JS
Hematology Am Soc Hematol Educ Program; 2013; 2013():247-53. PubMed ID: 24319187
[TBL] [Abstract][Full Text] [Related]
26. New directions in natural killer cell-based immunotherapy of human cancer.
Farag SS; Fehniger TA; Becknell B; Blaser BW; Caligiuri MA
Expert Opin Biol Ther; 2003 Apr; 3(2):237-50. PubMed ID: 12662139
[TBL] [Abstract][Full Text] [Related]
27. The rise of human stem cell-derived natural killer cells for cancer immunotherapy.
Wang K; Han Y; Cho WC; Zhu H
Expert Opin Biol Ther; 2019 Feb; 19(2):141-148. PubMed ID: 30583701
[TBL] [Abstract][Full Text] [Related]
28. Natural killer cell adoptive immunotherapy: Coming of age.
Baggio L; Laureano ÁM; Silla LMDR; Lee DA
Clin Immunol; 2017 Apr; 177():3-11. PubMed ID: 26883680
[TBL] [Abstract][Full Text] [Related]
29. Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.
Davis ZB; Vallera DA; Miller JS; Felices M
Semin Immunol; 2017 Jun; 31():64-75. PubMed ID: 28882429
[TBL] [Abstract][Full Text] [Related]
30. Translating the anti-myeloma activity of Natural Killer cells into clinical application.
Fionda C; Stabile H; Molfetta R; Soriani A; Bernardini G; Zingoni A; Gismondi A; Paolini R; Cippitelli M; Santoni A
Cancer Treat Rev; 2018 Nov; 70():255-264. PubMed ID: 30326421
[TBL] [Abstract][Full Text] [Related]
31. Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy.
Kwon HJ; Kim N; Kim HS
Exp Mol Med; 2017 Mar; 49(3):e311. PubMed ID: 28360428
[TBL] [Abstract][Full Text] [Related]
32. Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors.
Lian G; Mak TS; Yu X; Lan HY
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008589
[TBL] [Abstract][Full Text] [Related]
33. Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer.
Smits NC; Coupet TA; Godbersen C; Sentman CL
Expert Opin Biol Ther; 2016 Sep; 16(9):1105-12. PubMed ID: 27248342
[TBL] [Abstract][Full Text] [Related]
34. Challenges of NK cell-based immunotherapy in the new era.
Fang F; Xiao W; Tian Z
Front Med; 2018 Aug; 12(4):440-450. PubMed ID: 30047028
[TBL] [Abstract][Full Text] [Related]
35. Genetically re-engineered K562 cells significantly expand and functionally activate cord blood natural killer cells: Potential for adoptive cellular immunotherapy.
Ayello J; Hochberg J; Flower A; Chu Y; Baxi LV; Quish W; van de Ven C; Cairo MS
Exp Hematol; 2017 Feb; 46():38-47. PubMed ID: 27765614
[TBL] [Abstract][Full Text] [Related]
36. NK cells for cancer immunotherapy.
Shimasaki N; Jain A; Campana D
Nat Rev Drug Discov; 2020 Mar; 19(3):200-218. PubMed ID: 31907401
[TBL] [Abstract][Full Text] [Related]
37. "Adherent" versus Other Isolation Strategies for Expanding Purified, Potent, and Activated Human NK Cells for Cancer Immunotherapy.
Selvan SR; Dowling JP
Biomed Res Int; 2015; 2015():869547. PubMed ID: 26161419
[TBL] [Abstract][Full Text] [Related]
38. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy.
Wu Y; Li J; Jabbarzadeh Kaboli P; Shen J; Wu X; Zhao Y; Ji H; Du F; Zhou Y; Wang Y; Zhang H; Yin J; Wen Q; Cho CH; Li M; Xiao Z
Pharmacol Res; 2020 May; 155():104691. PubMed ID: 32070721
[TBL] [Abstract][Full Text] [Related]
39. Shaping of Natural Killer Cell Antitumor Activity by
Granzin M; Wagner J; Köhl U; Cerwenka A; Huppert V; Ullrich E
Front Immunol; 2017; 8():458. PubMed ID: 28491060
[TBL] [Abstract][Full Text] [Related]
40. Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review.
Phung CD; Tran TH; Kim JO
Arch Pharm Res; 2020 Jan; 43(1):32-45. PubMed ID: 31993969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
